Group 1 - The core issue of erectile dysfunction (ED) is increasingly recognized, with a prevalence rate of nearly 40% among men over 40 years old in China, and as high as 44.79% among those aged 31-40, indicating a trend towards younger patients [2][3] - The introduction of the domestic drug "Guanai" has significantly reduced the cost of ED treatment, priced at around 5 yuan per tablet, compared to 80-120 yuan for imported original drugs, making it a more accessible option for patients [3][4] - "Guanai" has passed the national consistency evaluation, ensuring its efficacy and safety are on par with original drugs, and is produced using high-purity European imported raw materials [4][5] Group 2 - The drug tadalafil, as a PDE5 inhibitor, offers a prolonged effect lasting up to 36 hours, making it suitable for chronic disease patients, such as those with hypertension and diabetes, thereby improving medication adherence [6] - The company aims to enhance patient willingness to use the drug by implementing a direct-to-consumer (F2C) model and providing online pharmacist services on e-commerce platforms [7][9] - "Guanai" not only focuses on selling medication but also on changing societal perceptions of ED through educational initiatives, helping men understand that ED is a treatable condition [10][12]